Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) is a leading biopharmaceutical company focused on developing treatments for serious diseases such as cancer, inflammatory, immunologic, cardiovascular, and fibrotic diseases. With a market cap of $111.2 billion, its strong oncology portfolio includes blockbuster drug Opdivo and other drugs like Revlimid, Pomalyst, Sprycel, Yervoy, and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. Shares of this ...

Core Insights - Three companies, Realty Income, Verizon, and Pfizer, have consistently raised their dividend payouts for over 16 years while offering attractive yields above 5% [2] Group 1: Realty Income - Realty Income has been providing monthly dividend payments for over 50 years, but its stock price has declined about 22% from its peak three years ago [4] - The company employs net leases, which ensure predictable cash flows, and has raised its dividend 131 times since going public in 1994 [5] - Realty Income's stock currently offers a yield of 5.5%, with total distributions in Q2 increasing by 3.7% year over year [6] - As of June, 98.6% of Realty Income's 15,606 properties were occupied, with an average lease term of nine years, ensuring steady cash flow growth [7] Group 2: Verizon - Verizon's stock is down about 28% from its all-time high in late 2019, yet it has raised its dividend for 18 consecutive years, currently offering a yield of 6.1% [8][9] - The company's wireless service revenue rose 2.2% year over year to $20.9 billion in Q2, contributing to a total revenue increase of 5.2% [9] - Verizon has raised its free cash flow forecast for 2025 to between $19.5 billion and $20.5 billion, indicating the ability to maintain dividends while reducing debt [10] Group 3: Pfizer - Pfizer's stock has decreased by about 59% from its 2021 peak, primarily due to concerns over expiring drug patents, but it has raised its dividend every year since 2009, currently offering a yield of 6.8% [11] - The company anticipates a revenue decline of $17 billion to $18 billion due to patent expirations starting in 2026, but it has prepared for this by acquiring Seagen for $43 billion [12] - By 2030, assets from Seagen and other acquisitions are expected to generate over $20 billion in annual sales, potentially allowing Pfizer to continue its dividend-raising streak [13]